Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling

Romany A N Johnpulle, Sophie Paczesny, Dae Kwang Jung, Etienne Daguindau, Madan H. Jagasia, Bipin N. Savani, Wichai Chinratanalab, Robert F. Cornell, Stacey Goodman, John P. Greer, Adetola A. Kassim, Salyka Sengsayadeth, Michael T. Byrne, Brian G. Engelhardt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

New-onset post-transplantation diabetes mellitus (PTDM) occurs commonly after allogeneic hematopoietic cell transplantation (HCT) and is associated with inferior survival. We hypothesize that PTDM and nonrelapse mortality (NRM) are related to IL-33/suppression of tumorigenicity 2 (ST2) signaling and that soluble ST2 (sST2) levels will predict PTDM diagnosis. sST2 was measured at engraftment and day +30 in 36 euglycemic HCT recipients followed prospectively for PTDM (cohort 1). Results were confirmed in a validation cohort of 26 patients without pre-existing diabetes analyzed retrospectively for PTDM (cohort 2). Twelve patients with established diabetes before HCT were analyzed in cohort 3. When compared with recipients without PTDM, patients developing PTDM (n = 24) from cohort 1 had elevated sST2 levels at engraftment (P = .02) and at day +30 (P < .01). Cohort 2 confirmed this finding at engraftment (P = .01). Cohort 3 patients with pretransplantation diabetes had higher sST2 at engraftment than patients maintaining euglycemia after HCT from cohort 2 (P = .03). Multivariate analysis of cohorts 1 and 2 showed high engraftment sST2 predicted increased PTDM and NRM risk, independent of conditioning and grades 3 to 4 acute graft-versus-host-disease. sST2 was elevated in PTDM, indicating a relationship between glucose homeostasis and the IL-33/ST2 axis after transplantation. Correction of metabolic complications may decrease sST2 and improve NRM.

Original languageEnglish (US)
Pages (from-to)529-532
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Transplantation
Diabetes Mellitus
Cell Transplantation
Mortality
Graft vs Host Disease
Homeostasis
Multivariate Analysis
Glucose
Survival
Interleukin-33

Keywords

  • Allogeneic
  • IL-33
  • Metabolic complications
  • Post-transplantation diabetes mellitus
  • Soluble suppression of tumorigenicity 2
  • sST2
  • Treatment-related mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling. / Johnpulle, Romany A N; Paczesny, Sophie; Jung, Dae Kwang; Daguindau, Etienne; Jagasia, Madan H.; Savani, Bipin N.; Chinratanalab, Wichai; Cornell, Robert F.; Goodman, Stacey; Greer, John P.; Kassim, Adetola A.; Sengsayadeth, Salyka; Byrne, Michael T.; Engelhardt, Brian G.

In: Biology of Blood and Marrow Transplantation, Vol. 23, No. 3, 01.03.2017, p. 529-532.

Research output: Contribution to journalArticle

Johnpulle, RAN, Paczesny, S, Jung, DK, Daguindau, E, Jagasia, MH, Savani, BN, Chinratanalab, W, Cornell, RF, Goodman, S, Greer, JP, Kassim, AA, Sengsayadeth, S, Byrne, MT & Engelhardt, BG 2017, 'Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling', Biology of Blood and Marrow Transplantation, vol. 23, no. 3, pp. 529-532. https://doi.org/10.1016/j.bbmt.2016.12.627
Johnpulle, Romany A N ; Paczesny, Sophie ; Jung, Dae Kwang ; Daguindau, Etienne ; Jagasia, Madan H. ; Savani, Bipin N. ; Chinratanalab, Wichai ; Cornell, Robert F. ; Goodman, Stacey ; Greer, John P. ; Kassim, Adetola A. ; Sengsayadeth, Salyka ; Byrne, Michael T. ; Engelhardt, Brian G. / Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling. In: Biology of Blood and Marrow Transplantation. 2017 ; Vol. 23, No. 3. pp. 529-532.
@article{6c7c8fbb92224bf9b0bfe15cc45568d7,
title = "Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling",
abstract = "New-onset post-transplantation diabetes mellitus (PTDM) occurs commonly after allogeneic hematopoietic cell transplantation (HCT) and is associated with inferior survival. We hypothesize that PTDM and nonrelapse mortality (NRM) are related to IL-33/suppression of tumorigenicity 2 (ST2) signaling and that soluble ST2 (sST2) levels will predict PTDM diagnosis. sST2 was measured at engraftment and day +30 in 36 euglycemic HCT recipients followed prospectively for PTDM (cohort 1). Results were confirmed in a validation cohort of 26 patients without pre-existing diabetes analyzed retrospectively for PTDM (cohort 2). Twelve patients with established diabetes before HCT were analyzed in cohort 3. When compared with recipients without PTDM, patients developing PTDM (n = 24) from cohort 1 had elevated sST2 levels at engraftment (P = .02) and at day +30 (P < .01). Cohort 2 confirmed this finding at engraftment (P = .01). Cohort 3 patients with pretransplantation diabetes had higher sST2 at engraftment than patients maintaining euglycemia after HCT from cohort 2 (P = .03). Multivariate analysis of cohorts 1 and 2 showed high engraftment sST2 predicted increased PTDM and NRM risk, independent of conditioning and grades 3 to 4 acute graft-versus-host-disease. sST2 was elevated in PTDM, indicating a relationship between glucose homeostasis and the IL-33/ST2 axis after transplantation. Correction of metabolic complications may decrease sST2 and improve NRM.",
keywords = "Allogeneic, IL-33, Metabolic complications, Post-transplantation diabetes mellitus, Soluble suppression of tumorigenicity 2, sST2, Treatment-related mortality",
author = "Johnpulle, {Romany A N} and Sophie Paczesny and Jung, {Dae Kwang} and Etienne Daguindau and Jagasia, {Madan H.} and Savani, {Bipin N.} and Wichai Chinratanalab and Cornell, {Robert F.} and Stacey Goodman and Greer, {John P.} and Kassim, {Adetola A.} and Salyka Sengsayadeth and Byrne, {Michael T.} and Engelhardt, {Brian G.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.bbmt.2016.12.627",
language = "English (US)",
volume = "23",
pages = "529--532",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling

AU - Johnpulle, Romany A N

AU - Paczesny, Sophie

AU - Jung, Dae Kwang

AU - Daguindau, Etienne

AU - Jagasia, Madan H.

AU - Savani, Bipin N.

AU - Chinratanalab, Wichai

AU - Cornell, Robert F.

AU - Goodman, Stacey

AU - Greer, John P.

AU - Kassim, Adetola A.

AU - Sengsayadeth, Salyka

AU - Byrne, Michael T.

AU - Engelhardt, Brian G.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - New-onset post-transplantation diabetes mellitus (PTDM) occurs commonly after allogeneic hematopoietic cell transplantation (HCT) and is associated with inferior survival. We hypothesize that PTDM and nonrelapse mortality (NRM) are related to IL-33/suppression of tumorigenicity 2 (ST2) signaling and that soluble ST2 (sST2) levels will predict PTDM diagnosis. sST2 was measured at engraftment and day +30 in 36 euglycemic HCT recipients followed prospectively for PTDM (cohort 1). Results were confirmed in a validation cohort of 26 patients without pre-existing diabetes analyzed retrospectively for PTDM (cohort 2). Twelve patients with established diabetes before HCT were analyzed in cohort 3. When compared with recipients without PTDM, patients developing PTDM (n = 24) from cohort 1 had elevated sST2 levels at engraftment (P = .02) and at day +30 (P < .01). Cohort 2 confirmed this finding at engraftment (P = .01). Cohort 3 patients with pretransplantation diabetes had higher sST2 at engraftment than patients maintaining euglycemia after HCT from cohort 2 (P = .03). Multivariate analysis of cohorts 1 and 2 showed high engraftment sST2 predicted increased PTDM and NRM risk, independent of conditioning and grades 3 to 4 acute graft-versus-host-disease. sST2 was elevated in PTDM, indicating a relationship between glucose homeostasis and the IL-33/ST2 axis after transplantation. Correction of metabolic complications may decrease sST2 and improve NRM.

AB - New-onset post-transplantation diabetes mellitus (PTDM) occurs commonly after allogeneic hematopoietic cell transplantation (HCT) and is associated with inferior survival. We hypothesize that PTDM and nonrelapse mortality (NRM) are related to IL-33/suppression of tumorigenicity 2 (ST2) signaling and that soluble ST2 (sST2) levels will predict PTDM diagnosis. sST2 was measured at engraftment and day +30 in 36 euglycemic HCT recipients followed prospectively for PTDM (cohort 1). Results were confirmed in a validation cohort of 26 patients without pre-existing diabetes analyzed retrospectively for PTDM (cohort 2). Twelve patients with established diabetes before HCT were analyzed in cohort 3. When compared with recipients without PTDM, patients developing PTDM (n = 24) from cohort 1 had elevated sST2 levels at engraftment (P = .02) and at day +30 (P < .01). Cohort 2 confirmed this finding at engraftment (P = .01). Cohort 3 patients with pretransplantation diabetes had higher sST2 at engraftment than patients maintaining euglycemia after HCT from cohort 2 (P = .03). Multivariate analysis of cohorts 1 and 2 showed high engraftment sST2 predicted increased PTDM and NRM risk, independent of conditioning and grades 3 to 4 acute graft-versus-host-disease. sST2 was elevated in PTDM, indicating a relationship between glucose homeostasis and the IL-33/ST2 axis after transplantation. Correction of metabolic complications may decrease sST2 and improve NRM.

KW - Allogeneic

KW - IL-33

KW - Metabolic complications

KW - Post-transplantation diabetes mellitus

KW - Soluble suppression of tumorigenicity 2

KW - sST2

KW - Treatment-related mortality

UR - http://www.scopus.com/inward/record.url?scp=85009815216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009815216&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.12.627

DO - 10.1016/j.bbmt.2016.12.627

M3 - Article

C2 - 28013014

AN - SCOPUS:85009815216

VL - 23

SP - 529

EP - 532

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -